{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:02Z","timestamp":1791563102753,"version":"4.3.4"},"reference-count":10,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15\u00a0years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a single histrelin implant for more than 12\u00a0months in children with CPP.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Implants were left in situ<\/jats:italic> for an average of 24\u00a0months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2022-0557","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T09:40:11Z","timestamp":1673343611000},"page":"309-312","source":"Crossref","is-referenced-by-count":7,"title":["Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-1052","authenticated-orcid":false,"given":"Lauren A.","family":"Ray","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology , Riley Hospital for Children at Indiana University Health , Indianapolis , IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Eckert","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science , Indiana University School of Medicine and Richard M. Fairbanks School of Public Health , Indianapolis , IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology , Riley Hospital for Children at Indiana University Health , Indianapolis , IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2023033123251283818_j_jpem-2022-0557_ref_001","doi-asserted-by":"crossref","unstructured":"Chen, M, Eugster, EA. Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 2015;17:273\u201381. https:\/\/doi.org\/10.1007\/s40272-015-0130-8.","DOI":"10.1007\/s40272-015-0130-8"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_002","doi-asserted-by":"crossref","unstructured":"Hirsch, HJ, Gillis, D, Strich, D, Chertin, B, Farkas, A, Lindenberg, T, et al.. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798\u2013802. https:\/\/doi.org\/10.1542\/peds.2005-0538.","DOI":"10.1542\/peds.2005-0538"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_003","doi-asserted-by":"crossref","unstructured":"Lewis, KA, Goldyn, AK, West, KW, Eugster, EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J\u00a0Pediatr 2013;163:1214\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2013.05.033.","DOI":"10.1016\/j.jpeds.2013.05.033"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_004","doi-asserted-by":"crossref","unstructured":"Rahhal, S, Clarke, WL, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:e812517. https:\/\/doi.org\/10.1155\/2009\/812517.","DOI":"10.1186\/1687-9856-2009-812517"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_005","doi-asserted-by":"crossref","unstructured":"Greulich, WW, Pyle, SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford: Stanford University Press; 1959.","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_006","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357\u201372. https:\/\/doi.org\/10.1159\/000501336.","DOI":"10.1159\/000501336"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_007","unstructured":"Lupkin, S. Hormone blocker sticker shock: kids drug costs 8 times more than one for adults; 2020. Available from: https:\/\/www.npr.org\/sections\/health-shots\/2020\/02\/24\/808049526\/hormone-blocker-sticker-shock-kids-drug-costs-8-times-more-than-one-for-adults [Accessed 29 Jul 2022]."},{"key":"2023033123251283818_j_jpem-2022-0557_ref_008","doi-asserted-by":"crossref","unstructured":"Davis, JS, Alkhoury, F, Burnweit, C. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty. J Pediatr Surg 2014;49:807\u201310. https:\/\/doi.org\/10.1016\/j.jpedsurg.2014.02.067.","DOI":"10.1016\/j.jpedsurg.2014.02.067"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_009","doi-asserted-by":"crossref","unstructured":"Silverman, LA, Neely, EK, Kletter, GB, Lewis, K, Chitra, S, Terleckyj, O, et al.. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab 2015;100:2354\u201363. https:\/\/doi.org\/10.1210\/jc.2014-3031.","DOI":"10.1210\/jc.2014-3031"},{"key":"2023033123251283818_j_jpem-2022-0557_ref_010","doi-asserted-by":"crossref","unstructured":"Villalta, D, Quintos, JB. Gonadotropin suppression for 7 years after a\u00a0single histrelin implant for precocious puberty. J Endocr Soc 2022;6:bvab189. https:\/\/doi.org\/10.1210\/jendso\/bvab189.","DOI":"10.1210\/jendso\/bvab189"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0557\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T12:21:40Z","timestamp":1680351700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0557\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,6]]},"published-print":{"date-parts":[[2023,3,28]]}},"alternative-id":["10.1515\/jpem-2022-0557"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2022-0557","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}